SCHEMBL2834797

SCHEMBL2834797

CC(C)(C)OC(=O)NC(C(=O)c1ccc(-c2cccc(C(N)=O)c2)cc1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 1/20 0.46
PTGES2 Q9H7Z7 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
F10 P00742 1/20 0.38
PLG P00747 1/20 0.38
PRSS1 P07477 1/20 0.38
MDM2 Q00987 1/20 0.38
PLAU P00749 1/20 0.38
PLAT P00750 1/20 0.38
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
OPRK1 P41145 1/20 0.37
UTS2R Q9UKP6 1/20 0.37
CYP17A1 P05093 1/20 0.37
CSF1R P07333 1/20 0.36
FLT1 P17948 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2833255 0.86 S1PR3 (0.45) S1PR3CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL2833345 0.86 RXRA (0.47) S1PR3CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL2833996 0.84 S1PR3 (0.44) S1PR3CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL2833271 0.82 S1PR3 (0.47) S1PR3PTGES2MEN1KMT2ACYP3A4
SCHEMBL2835001 0.81 S1PR3 (0.48) S1PR3CYP1A2CYP2C9CYP2C19MDM2
SCHEMBL2836642 0.80 S1PR3 (0.48) S1PR3CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL2833750 0.80 S1PR3 (0.48) S1PR3MDM2CTSSCTSK
SCHEMBL2833350 0.80 S1PR3 (0.50) S1PR3MDM2CYP3A4CYP2D6CTSB
SCHEMBL2832303 0.79 S1PR3 (0.49) S1PR3CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL2835057 0.79 S1PR3 (0.48) S1PR3MDM2CTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885PTGES2 3553/4885CYP1A2 477/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885PTGES2 3553/4885CYP1A2 477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.